Begoña Bermejo - Concepedia

Author

Begoña Bermejo

Hospital Clínico Universitario de Valencia ORCID

Also Known As

B BERMEJO, B Bermejo, B. Bermejo, B. bermejo, Begona Bermejo, Begoña Bermejo, Begoña Bermejo, Begoña Bermejo de Las Heras, Begoña Bermejo de las Heras, Bermejo, Begoña

630

Publications

6.5K

Citations

H-Index

Concepts

All Affiliations

Hospital Clínico Universitario de Valencia Centro de Investigación Biomédica en Red de Cáncer INCLIVA Health Research Institute Vall d'Hebron Hospital Universitari Universitat de València

About

Begoña Bermejo is an author at Hospital Clínico Universitario de Valencia specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	41	2.4K
2	Health Sciences	10	10	202
3	Engineering	2	2	36
4	Language Studies	1	1	20
5	Allergy	1	1	14

Begoña Bermejo

104

Publications

5.7K

Citations

H-Index

Page 1

	Year	Citations
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study Luca Gianni, Chiun‐Sheng Huang, Daniel Egle, Annals of Oncology Advanced Breast CancerBreast OncologyOncologyPathologic Complete ResponsePathology	2022	365
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial Antonio Llombart‐Cussac, Javier Cortés, Laia Paré, The Lancet Oncology Breast OncologyMedicinePathologyPathological Complete ResponseImmune Checkpoint Inhibitor	2017	329
Spatial predictors of immunotherapy response in triple-negative breast cancer Xiao Qian Wang, Esther Danenberg, Chiun‐Sheng Huang, Nature	2023	278
Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study Aleix Prat, Giampaolo Bianchini, Marlène Thomas, Clinical Cancer Research	2014	232
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade Aleix Prat, Tomás Pascual, Carmine De Angelis, JNCI Journal of the National Cancer Institute	2019	163
Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer José Baselga, J. G. M. Segalla, Henri Roché, Journal of Clinical Oncology	2012	160
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With <i>ERBB2/HER2</i> -Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial Luca Gianni, Mauro Mansutti, Antonio Antón, JAMA Oncology	2018	153
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial José Manuel Pérez-García, Géraldine Gebhart, Manuel Ruíz Borrego, The Lancet Oncology Breast OncologyMedicineChemotherapy De-escalationPathologyImmune Checkpoint Inhibitor	2021	152
FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer Mafalda Oliveira, Cristina Saura, Paolo Nucíforo, Annals of Oncology Breast OncologyPhase Ii TrialMedicinePharmacologyClinical Trials	2019	149
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer Ana C. Garrido-Castro, Cristina Saura, Romualdo Barroso‐Sousa, Breast Cancer Research	2020	141

Page 1